Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies

被引：44
|
作者：
Schoenfeld, Kurt [1 ]
Zuber, Chantal [1 ]
Pinkas, Jan [2 ]
Haeder, Thomas [1 ]
Bernoester, Katrin [1 ]
Uherek, Christoph [1 ]
机构：
[1] Biotest AG, Landsteinerstr 5, D-63303 Dreieich, Germany
[2] ImmunoGen Inc, 830 Winter St, Waltham, MA 02451 USA
来源：
JOURNAL OF HEMATOLOGY & ONCOLOGY | 2017年 / 10卷
关键词：
Multiple myeloma; Pre-clinical; Indatuximab ravtansine; Drug combination; Tumour regression; AGENTS;
D O I：
10.1186/s13045-016-0380-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/ dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies
    Gugliandolo, Agnese
    Bramanti, Placido
    Mazzon, Emanuela
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 35
  • [42] Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model
    Bekri, Selma
    Uduman, Mohamed
    Gruenstein, Diana
    Mei, Anna Huo-Chang
    Tung, Kaity
    Rodney-Sandy, Reunet
    Bogen, Bjarne
    Buell, Jennifer
    Stein, Robert
    Doherty, Kaitlin
    Findeis, Mark
    Morin, Benjamin
    Joshi, Bishnu
    Tanne, Antoine
    Castle, John
    Levey, Daniel
    Cho, Hearn Jay
    BLOOD, 2017, 130
  • [43] Activity of Orally Available CBP/p300 Degraders in Pre-Clinical Models of Multiple Myeloma
    Tiwari, Praveen Kumar
    Harrison, Drew A.
    Ojeda, Samuel
    Kawale, Ajinkya S.
    Doda, Sai Reddy
    Uannam, Raghu
    Karakyriakou, Barbara
    Koglin, Ann-Sophie
    Rizvi, Sarah
    Ott, Christopher J.
    BLOOD, 2024, 144 : 2795 - 2795
  • [44] Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation
    McMillin, Douglas W.
    Delmore, Jake
    Negri, Joseph
    Ooi, Melissa
    Klippel, Steffen
    Miduturu, Chandrasekhar V.
    Gray, Nathanael S.
    Richardson, Paul G.
    Anderson, Kenneth C.
    Kung, Andrew L.
    Mitsiades, Constantine S.
    PLOS ONE, 2011, 6 (07):
  • [45] Pre-clinical models of genetically heterogeneous multiple myeloma reveal mechanisms of immune escape and predict clinical immunotherapy outcomes
    Larrayoz, Marta
    Garcia-Barchino, Maria J.
    Celay, Jon
    Etxebeste, Amaia
    Jimenez, Maddalen
    Perez, Cristina
    Ordonez, Raquel
    Cobaleda, Cesar
    Chesi, Marta
    Bergsagel, Leif
    Rodriguez-Otero, Paula
    Takahashi, Satoru
    Katz, Samuel G.
    Walensky, Loren D.
    Ruppert, Shannon M.
    Lasater, Elisabeth A.
    Amann, Maria
    Lasarte, Juan J.
    Kurilovich, Anna
    Cerchietti, Leandro
    Agirre, Xabier
    San-Miguel, Jesus
    Paiva, Bruno
    Prosper, Felipe
    Martinez-Climent, Jose A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S19 - S20
  • [46] Combination targeted therapy in chronic lymphocytic leukaemia - can pre-clinical studies translate to the clinic?
    Ioannou, Nikolaos
    Ramsay, Alan G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (03) : 315 - 316
  • [47] Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies
    Harry Fagan
    Edward Jones
    David S. Baldwin
    CNS Drugs, 2023, 37 : 1 - 12
  • [48] Monte Carlo Based Treatment Planning Workflow for Pre-Clinical and Clinical Electron Flash Studies
    Ashraf, M. R.
    Melemenidis, S.
    Schulz, J. B.
    Loo, B. W., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E96 - E97
  • [49] Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies
    Fagan, Harry
    Jones, Edward
    Baldwin, David S.
    CNS DRUGS, 2023, 37 (01) : 1 - 12
  • [50] A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma
    Ramachandran, Indu R.
    Lin, Cindy
    Chase, Tess
    Gabrilovich, Dmitry
    Nefedova, Yulia
    BLOOD, 2014, 124 (21)
12345